Infliximab and Biosimilar Yield Similar Results in IBD

New data supported the safety and efficacy of nonmedical switching from infliximab to a biosimilar, according to researchers.

Related Keywords

Canada ,United Kingdom ,Vancouver ,British Columbia ,Canadian ,British ,Thomas Tam Hoang ,Laura Targownik ,University Of Toronto Temerty Faculty Medicine ,Centre Of British Columbia ,Journal Of The Canadian Association Gastroenterology ,Health Canada ,University Of British Columbia Faculty Medicine ,British Columbia Faculty ,Medscape Medical ,Canadian Association ,Medscape Medical News ,Mount Sinai Hospital ,Temerty Faculty ,Inflammatory Bowel Disease Ibd ,Biologic Therapy ,Iologics ,Biosimilars ,Biosimilar Drugs ,Follow On Biologics ,Board Certification ,Boards ,Oard Recertification ,Crohn 039s Disease ,Crohn Disease ,Egional Enteritis Crohn S ,Ulcerative Colitis ,Lcerative Colitis Uc ,C Ulcerative Colitis ,Colitis ,Computed Tomography ,It ,Ct Scan ,Grant ,Anti Tnf ,